News|Articles|September 13, 2023
EMPOWERing the Next Generation
Author(s)Erica Koenig, PhD
Key Takeaways
- Leadership for emraclidine resides with Erica Koenig, PhD, who is program lead and senior director of global clinical development at Cerevel Therapeutics.
- EMPOWER is a phase 2 clinical trial evaluating emraclidine as a potential treatment option for schizophrenia.
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
Advertisement
CONFERENCE REPORTER
Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress® 2023.
Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.
The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by any third-party. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of any third-parties.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression
2
Suicide Risk Assessment in Patients Denying Suicidal Intent
3
Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD
4
Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability
5